Heart failure & cardiomyopathiesCohort study
Longitudinal trajectories of neurodegenerative biomarkers in the blood of patients with chronic heart failure
- prospective Cognition.Matters-HF cohort study
Authors' conclusion
In clinically stable patients with chronic HF, longitudinal increases in circulating amyloid-β peptides associated with cognitive decline, structural brain changes, and mortality. Serial biomarker assessment provided stronger prognostic information than baseline measurements alone. Replication in larger cohorts is required.
Study context
- Population
- Patients with chronic heart failurepatients with chronic heart failure (HF) (10% female, age 64 ± 10 years)
- Participants
- 104 patients
Main finding
As reported in the abstract
All biomarkers except NfL increased significantly over 3 years
P < .05
Observational data: associations, not effects.
Further findings
Median annual percentage changes
- phosphorylated tau protein-181
- 36.6%
- glial fibrillary acidic protein
- 4.6%
- β-synuclein
- 2.6%
- Aβ38
- 0.6%
- Aβ40
- 0.5%
- Aβ42
- 0.3%
Increases in Aβ38 and Aβ42 and future mild cognitive impairment (MCI), pathological white matter hyperintensity progression (>5% per year), and 5-year mortality
- Increases in Aβ38 and Aβ42 independently associated with future MCI, pathological white matter hyperintensity progression (>5% per year), and 5-year mortality
- all P < .05
- After adjusting for clinical confounders
Pathological brain atrophy (>0.3% per year)
- Glial fibrillary acidic protein levels and phosphorylated tau protein-181 trajectories independently associated with pathological brain atrophy
Original publication
Summarised from the published abstract; every number is checked against it